Current status of antiretroviral therapy

被引：60

作者：

Temesgen, Zelalem ^{[1
]}

Warnke, David ^{[1
]}

Kasten, Mary J. ^{[1
]}

机构：

[1] Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN 55905 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 12期

关键词：

antiretrovirals; antiretroviral therapy; chemokine receptor antagonists; entry inhibitors; fusion inhibitors; highly active antiretroviral therapy; HIV; integrase inhibitors; maturation inhibitors; non-nucleoside analogue reverse transcriptase inhibitors; nucleoside analogue reverse transcriptase inhibitors; protease inhibitors; treatment guidelines;

D O I：

10.1517/14656566.7.12.1541

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.

引用

页码：1541 / 1554

页数：14

共 54 条

[31] INHIBITION OF HIV-1 REPLICATION BY A NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR [J].

MERLUZZI, VJ ;

HARGRAVE, KD ;

LABADIA, M ;

GROZINGER, K ;

SKOOG, M ;

WU, JC ;

SHIH, CK ;

ECKNER, K ;

HATTOX, S ;

ADAMS, J ;

ROSEHTHAL, AS ;

FAANES, R ;

ECKNER, RJ ;

KOUP, RA ;

SULLIVAN, JL .

SCIENCE, 1990, 250 (4986) :1411-1413

[32] INHIBITION OF THE INVITRO INFECTIVITY AND CYTOPATHIC EFFECT OF HUMAN LYMPHOTROPHIC-T VIRUS "TYPE-III/LYMPHADENOPATHY-ASSOCIATED VIRUS (HTLV-III/LAV) BY 2',3'-DIDEOXYNUCLEOSIDES [J].

MITSUYA, H ;

BRODER, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (06) :1911-1915

[33] The entry of entry inhibitors: A fusion of science and medicine [J].

Moore, JP ;

Doms, RW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (19) :10598-10602

[34] Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection [J].

Moyle, GJ ;

Wildfire, A ;

Mandalia, S ;

Mayer, H ;

Goodrich, J ;

Whitcomb, J ;

Gazzard, BG .

JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (06) :866-872

[35]

NAVIA MA, 1989, NATURE, V159, P87

[36] Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies [J].

Negredo, E ;

Bonjoch, A ;

Paredes, R ;

Puig, J ;

Clotet, B .

CLINICAL INFECTIOUS DISEASES, 2005, 41 (06) :901-905

[37]

Núñez M, 2001, J ACQ IMMUN DEF SYND, V27, P426, DOI 10.1097/00126334-200108150-00002

[38] Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection [J].

Palella, FJ ;

Delaney, KM ;

Moorman, AC ;

Loveless, MO ;

Fuhrer, J ;

Satten, GA ;

Aschman, DJ ;

Holmberg, SD .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) :853-860

[39] HIV-1 coreceptor usage, transmission, and disease progression [J].

Philpott, SM .

CURRENT HIV RESEARCH, 2003, 1 (02) :217-227

[40] HIV-1 PROTEASE INHIBITORS - THEIR DEVELOPMENT, MECHANISM OF ACTION AND CLINICAL POTENTIAL [J].

PILLAY, D ;

BRYANT, M ;

GETMAN, D ;

RICHMAN, DD .

REVIEWS IN MEDICAL VIROLOGY, 1995, 5 (01) :23-33

← 1 2 3 4 5 6 →